PCV Vaccination Schedule for Children (IAP Guidelines)
For healthy infants starting at 2 months of age, administer PCV13 as a 4-dose series at 2,4,6, and 12-15 months of age, with the booster dose given at least 8 weeks after the third dose. 1
Routine Primary Series (No Previous Vaccination)
Infants 2-6 Months
- 3 primary doses given 8 weeks apart (minimum 4 weeks interval acceptable)
- Fourth (booster) dose at 12-15 months, at least 8 weeks after dose 3
- First dose can be given as early as 6 weeks of age 1
- For premature infants (<37 weeks gestation), use chronologic age for scheduling 1
Late Starters: Infants 7-11 Months
- 3 total doses required 1
- First 2 doses: minimum 4 weeks apart
- Third dose: at 12-15 months, at least 8 weeks after second dose
Late Starters: Children 12-23 Months
- 2 doses required, minimum 8 weeks apart 1
Late Starters: Children 24-59 Months (Healthy)
- Single dose only 1
Children 24-71 Months with High-Risk Conditions
- 2 doses, minimum 8 weeks apart 1
- High-risk conditions include: asplenia, sickle cell disease, immunocompromising conditions, HIV, cochlear implants, CSF leaks
Catch-Up Schedules for Incomplete Vaccination
Children <24 Months with Prior PCV7/PCV13
Complete the series with PCV13 based on current age and doses received 1:
If 2-3 doses received before 12 months:
- Give 1 dose of PCV13 at ≥8 weeks after most recent dose
- This completes the series (no additional doses needed if already received ≥1 PCV13 dose at ≥12 months) 1
If received complete PCV7 series (4 doses):
- Give 1 supplemental PCV13 dose ≥8 weeks after last PCV7 dose 1
Children 24-59 Months (Healthy) with Incomplete Schedule
- 1 dose of PCV13, regardless of previous PCV7/PCV13 history 1
- Minimum 8 weeks after most recent dose
Children 24-71 Months (High-Risk) with Incomplete Schedule
- If <3 previous doses: Give 2 doses of PCV13, 8 weeks apart 1
- If 3 previous doses: Give 1 dose of PCV13 1
Special Populations
Children 6-18 Years with High-Risk Conditions
A single dose of PCV13 may be given to previously unvaccinated children with:
- Anatomic/functional asplenia (including sickle cell disease)
- Immunocompromising conditions (HIV)
- Cochlear implants
- CSF leaks 1
Not recommended for routine use in healthy children ≥5 years 1
Key Clinical Considerations
Minimum Intervals:
- Between doses in infants <12 months: 4 weeks (8 weeks preferred) 1
- Between doses in children ≥12 months: 8 weeks 1
- Between last PCV7 and PCV13: 8 weeks 1
Common Pitfall: The evidence shows that while 2-dose infant schedules (2+1) provide adequate protection after the booster, they result in higher vaccine-type carriage and breakthrough infections before the booster compared to 3-dose schedules (3+1) 2, 3. The 4-dose schedule (3 primary + 1 booster) provides optimal protection throughout infancy and early childhood.
Practical Note: Interruption of the schedule does not require restarting the series or adding extra doses—simply continue from where the child left off 1. However, achieving high coverage with the recommended number of doses is more important than the specific timing 4.
Newer Formulations: While PCV20 (20-valent) is now FDA-approved for children ≥6 weeks with similar dosing schedules 5, the IAP guidelines referenced here focus on PCV13, which remains the standard in most settings. PCV20 follows the same 4-dose schedule (2,4,6,12-15 months) with comparable catch-up recommendations 5.